Profile
Sector:
HealthcareIndustry:
BiotechnologyCountry:
United StatesIPO:
08 November 2019Website:
http://www.cnspharma.comNext earnings report:
14 August 2024Last dividends:
N/ANext dividends:
N/APrice
after hours | Wed, 03 Jul 2024 20:59:45 GMTDividend
Analysts recommendations
Institutional Ownership
CNSP Latest News
HOUSTON, TX / ACCESSWIRE / April 1, 2024 / CNS Pharmaceuticals, Inc. (NASDAQ:CNSP) ("CNS" or the "Company"), a biopharmaceutical company specializing in the development of novel treatments for primary and metastatic cancers in the brain and central nervous system, today announced that John Climaco, Chief Executive Officer of CNS Pharmaceuticals will present at two upcoming investor conferences being held in New York City in April. In addition to the presentations, management will be available to participate in one-on-one meetings with qualified members of the investor community who are registered to attend the respective conferences.
Live webcast presentation on Wednesday, September 13th at 10:30 AM ET HOUSTON, TX / ACCESSWIRE / September 5, 2023 / CNS Pharmaceuticals, Inc. (NASDAQ:CNSP) ("CNS" or the "Company"), a biopharmaceutical company specializing in the development of novel treatments for primary and metastatic cancers in the brain and central nervous system, today announced that John Climaco, CEO of CNS Pharmaceuticals, will present at the H.C. Wainwright 25th Annual Global Investment Conference being held in New York, NY on Wednesday, September 13, 2023 at 10:30 AM ET.
Live moderated video webcast with members of CNS Pharmaceuticals management on Wednesday, May 3rd at 12:00 PM ET HOUSTON, TX / ACCESSWIRE / April 27, 2023 / CNS Pharmaceuticals, Inc. (NASDAQ:CNSP) ("CNS" or the "Company"), a biopharmaceutical company specializing in the development of novel treatments for primary and metastatic cancers in the brain and central nervous system, today announced that it will present at the Virtual Investor Spotlight Event - Rapidly Advancing GBM Pivotal Study on Wednesday, May 3, 2023 at 12:00 PM ET. As part of the event, John Climaco, Chief Executive Officer, Sandra Silberman, MD, PhD, Chief Medical Officer and Zena Muzyczenko, Vice President, Clinical Operations of CNS Pharmaceuticals will discuss the progress of its ongoing potentially pivotal study evaluating Berubicin for the treatment of recurrent glioblastoma multiforme (GBM), one of the most aggressive types of brain cancer.
Investing in energy penny stocks? Here's some top tips The post Buying Energy Penny Stocks?
Live moderated video webcast with members of CNS Pharmacetucals management and Key Opinion Leader, Professor Michael Weller, MD, on Tuesday, April 4 th at 3:00 PM ET HOUSTON , March 29, 2023 /PRNewswire/ -- CNS Pharmaceuticals, Inc. (NASDAQ: CNSP) ("CNS" or the "Company"), a biopharmaceutical company specializing in the development of novel treatments for primary and metastatic cancers in the brain and central nervous system, today announced that it will present at the Virtual Investor GBM Spotlight Event on Tuesday, April 4, 2023 at 3:00 PM ET. As part of the event, John Climaco, Chief Executive Officer of CNS Pharmaceuticals will be joined by Key Opinion Leader Professor Michael Weller, MD, to discuss GBM, the unmet need and the work CNS Pharmaceuticals is doing to advance Berubicin for the treatment of recurrent glioblastoma multiforme (GBM), one of the most aggressive types of brain cancer.
What type of business is CNS Pharmaceuticals?
CNS Pharmaceuticals, Inc., a clinical pharmaceutical company, engages in the development of anti-cancer drug candidates for the treatment of brain and central nervous system tumors. The company's lead drug candidate is Berubicin, an anthracycline that is in Phase I and II clinical trials that is used for the treatment of glioblastoma multiforme. It has license agreements with Houston Pharmaceuticals, Inc. and The University of Texas M.D. Anderson Cancer Center, as well as Animal Life Sciences, LLC; and a development agreement with WPD Pharmaceuticals Inc., as well as a collaboration agreement with Reata Pharmaceuticals, Inc. The company was incorporated in 2017 and is based in Houston, Texas.
What sector is CNS Pharmaceuticals in?
CNS Pharmaceuticals is in the Healthcare sector
What industry is CNS Pharmaceuticals in?
CNS Pharmaceuticals is in the Biotechnology industry
What country is CNS Pharmaceuticals from?
CNS Pharmaceuticals is headquartered in United States
When did CNS Pharmaceuticals go public?
CNS Pharmaceuticals initial public offering (IPO) was on 08 November 2019
What is CNS Pharmaceuticals website?
https://www.cnspharma.com
Is CNS Pharmaceuticals in the S&P 500?
No, CNS Pharmaceuticals is not included in the S&P 500 index
Is CNS Pharmaceuticals in the NASDAQ 100?
No, CNS Pharmaceuticals is not included in the NASDAQ 100 index
Is CNS Pharmaceuticals in the Dow Jones?
No, CNS Pharmaceuticals is not included in the Dow Jones index
When does CNS Pharmaceuticals report earnings?
The next expected earnings date for CNS Pharmaceuticals is 14 August 2024